#27 JournalChat // COVID Trials & Immunomodulation with Dr James Galloway
Looking for the right gateway drug to help start up an insatiable medical literature habit? JournalJunkies, your ears are in the right place!Today we interview Dr James Galloway, rheumatologist, semi- ornithologist, clinical lecturer, and head of the TACTIC trial at King's Hospital.He helps guide us through the mysteries of immunomodulation in COVID in understandable terms. What do the trials show us? Why? And, what is on the COVID horizon? 02:00 Introductions02:45 Why the birds aren't coming to your garden04:45 The Recovery Trial08:00 Why Steroids?09:35 REMAP CAP13:45 The conflicting Tocilizumab data17: 40 What is Tocilizumab and why might it work?24:50 The value of CRP monitoring27:00 Who to give Tocilizumab to29:40 TACTIC trial34:30 Why study SGLT2 inhibitors37:00 The future Tx of Severe COVID40:00 The JournalSpotting Gateway drugSupport the showVisit the website on www.journalspotting.com. Follow us on Twitter @JournalSpotting.Email us on journalspotting@gmail.com.Get our JournalClub App on https://journalclub.messly.comShare us with all your colleagues!